Significant Ownership of Laurence W. Lytton
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Laurence W. Lytton focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Laurence W. Lytton - Reporting Person
- Manager location
- NY, NY
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Laurence W. Lytton with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Laurence W. Lytton
Significant Ownership of Laurence W. Lytton
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| MDXH | MDxHealth SA | Ordinary Shares | 20% | $9,465,084 | +$6,943,917 | 18,558,988 | +275% | Laurence W. Lytton | 13 Aug 2026 |
| GUER | GUERRILLA RF, INC. | Common Stock | 10% | $3,048,798 | +$23,661 | 1,096,690 | +0.78% | Lytton, Laurence W. | 30 Jun 2026 |
| LIQT | LIQTECH INTERNATIONAL INC | Common Stock | 10% | $2,601,312 | +$1,786,261 | 3,378,327 | +219% | LYTTON LAURENCE W | 30 Jun 2026 |
| SINT | Sintx Technologies, Inc. | Common Stock | 10% | $1,505,667 | 632,633 | LYTTON LAURENCE W | 03 Jun 2026 | ||
| INAB | IN8BIO, INC. | Common Stock | 10% | $1,489,683 | +$102,200 | 1,056,513 | +7.4% | LYTTON LAURENCE W | 30 Jun 2026 |
| SNAX | STRYVE FOODS, INC. | Class A Common Stock | 10% | $265,402 | 414,755 | LYTTON LAURENCE W | 31 Dec 2025 | ||
| DAIO | DATA I/O CORP | Common Stock | 9.9% | $2,832,930 | 1,026,424 | LYTTON LAURENCE W | 17 Jun 2026 | ||
| SCND | SCIENTIFIC INDUSTRIES INC | Common Stock | 9.9% | $784,682 | 1,245,527 | Lytton-Kambara Foundation | 30 Jun 2026 | ||
| CLRB | Cellectar Biosciences, Inc. | Common Stock | 8.8% | $1,147,086 | 3,955,470 | LYTTON LAURENCE W | 31 Dec 2024 | ||
| CREX | CREATIVE REALITIES, INC. | Common Stock | 8.7% | 914,158 | LYTTON LAURENCE W | 31 Mar 2026 | |||
| SONM | DNA X, Inc. | Common Stock | 8.1% | 120,357 | LYTTON LAURENCE W | 31 Mar 2026 | |||
| IPWR | Ideal Power Inc. | Common Stock | 7.5% | $4,837,674 | -$1,260,963 | 959,856 | -21% | LYTTON LAURENCE W | 30 Jun 2026 |
| SONM | DNA X, Inc. | Common Stock | 6.8% | $70,365 | -$33,438 | 100,521 | -32% | LYTTON LAURENCE W | 30 Jun 2026 |
| ELWT | Elauwit Connection, Inc. | Common Stock | 5.9% | $3,005,860 | 390,879 | LYTTON LAURENCE W | 15 Dec 2025 | ||
| XTNT | Xtant Medical Holdings, Inc. | Common Stock | 5.5% | $5,545,441 | -$1,268,237 | 7,702,002 | -19% | LYTTON LAURENCE W | 31 Dec 2025 |
| TELA | TELA Bio, Inc. | Common Stock | 5.5% | $1,465,405 | -$253,778 | 2,442,341 | -15% | Lytton, Laurence W. | 31 Mar 2026 |
| CEPL | Capstone Energy Plus, Inc. | Common Stock | 5.4% | $17,989,578 | -$255,883 | 1,746,561 | -1.4% | LYTTON LAURENCE W | 30 Jun 2026 |
| CDXS | Codexis, Inc. | Common Stock | 5.2% | $12,640,117 | +$2,397,641 | 5,592,972 | +23% | LYTTON LAURENCE W | 30 Jun 2026 |
| ROC | Rank One Computing Corp | Common Stock | 5.1% | $4,297,063 | 967,807 | Laurence W. Lytton | 14 Aug 2026 | ||
| CREX | CREATIVE REALITIES, INC. | Common Stock | 5.1% | $1,223,591 | +$213,230 | 534,436 | +21% | LYTTON LAURENCE W | 28 Oct 2025 |
| DUOT | DUOS TECHNOLOGIES GROUP, INC. | Common Stock | 5% | $2,732,813 | 427,002 | LYTTON LAURENCE W | 31 Jan 2024 | ||
| AYTU | AYTU BIOPHARMA, INC | Common Stock | 5% | $1,228,378 | -$1,182,161 | 545,946 | -49% | LYTTON LAURENCE W | 30 Jun 2026 |
| RNTX | Rein Therapeutics, Inc. | Common Stock | 4.9% | $4,196,242 | -$258,758 | 4,238,628 | -5.8% | LYTTON LAURENCE W | 30 Jun 2026 |
| SMTK | SmartKem, Inc. | Common Stock | 4.9% | $525,622 | -$261,044 | 222,721 | -33% | Lytton, Laurence W. | 31 Mar 2025 |
| ELVA | Electrovaya Inc. | Common Shares | 4.7% | $7,272,871 | -$2,085,002 | 1,898,922 | -22% | Lytton, Laurence W. | 30 Jun 2025 |
| EVOK | Evoke Pharma Inc | Common Stock, par value $0.0001 | 3.9% | $158,087 | 61,274 | Lytton, Laurence W. | 31 Mar 2025 | ||
| BFRI | Biofrontera Inc. | Common Stock, par value $0.001 | 3.5% | $254,561 | 306,700 | LYTTON LAURENCE W | 31 Mar 2025 | ||
| APRE | Aprea Therapeutics, Inc. | Common Stock | 3.2% | $293,105 | -$218,272 | 390,807 | -43% | LYTTON LAURENCE W | 30 Jun 2026 |
| NMTC | NEUROONE MEDICAL TECHNOLOGIES Corp | Common Stock, par value $0.001 | 2.6% | $764,220 | 1,295,288 | LYTTON LAURENCE W | 31 Mar 2025 | ||
| TLPH | TALPHERA, INC. | Common Stock | 2.5% | $1,009,620 | -$1,202,262 | 1,246,444 | -54% | LYTTON LAURENCE W | 31 Mar 2026 |
| CLRB | Cellectar Biosciences, Inc. | Common Stock | 1.6% | $250,788 | 51,391 | LYTTON LAURENCE W | 30 Jun 2025 | ||
| EMKR | EMCORE CORP | Common Stock | 1.4% | $394,948 | 126,948 | LYTTON LAURENCE W | 31 Dec 2024 | ||
| XGN | EXAGEN INC. | Common Stock, par value $0.001 per share | 1% | $1,481,017 | 216,840 | LYTTON LAURENCE W | 30 Jun 2025 | ||
| SCPH | scPharmaceuticals Inc. | Common Stock | 0% | $0 | 0 | LYTTON LAURENCE W | 30 Sep 2025 |
Schedules 13D/G Reported by Laurence W. Lytton:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.